Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Lijie Zhai; Erik Ladomersky; Kristen L. Lauing; Meijing Wu; Denise M. Scholtens; Rohan Savoor; Bin Zhang; Jennifer D. Wu; Craig Horbinski; Rimas V. Lukas; David C. Binder; Derek A. Wainwright

doi:10.1080/2162402X.2018.1548242

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

Original language	English (US)
Article number	1548242
Journal	OncoImmunology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1080/2162402X.2018.1548242
State	Published - Mar 4 2019

Funding

This work was supported by NIH grants R00 NS082381 (D.A.W.); R01 NS097851-01 (D.A.W.); National Cancer Institute P50 CA221747 Project 2 (D.A.W. and R.V.L.), and T32 CA0070085 (E.L.).

Keywords

IDO
Treg
brain tumor
glioblastoma
immunosuppression
immunotherapy

ASJC Scopus subject areas

Oncology
Immunology and Allergy
Immunology

Access to Document

10.1080/2162402X.2018.1548242

Cite this

Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Scholtens, D. M., Savoor, R., Zhang, B., Wu, J. D., Horbinski, C., Lukas, R. V., Binder, D. C., & Wainwright, D. A. (2019). Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). OncoImmunology, 8(3), Article 1548242. https://doi.org/10.1080/2162402X.2018.1548242

@article{62dd6ea27ea540a2b0b96845a84ce77d,

title = "Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)",

abstract = "Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.",

keywords = "IDO, Treg, brain tumor, glioblastoma, immunosuppression, immunotherapy",

author = "Lijie Zhai and Erik Ladomersky and Lauing, {Kristen L.} and Meijing Wu and Scholtens, {Denise M.} and Rohan Savoor and Bin Zhang and Wu, {Jennifer D.} and Craig Horbinski and Lukas, {Rimas V.} and Binder, {David C.} and Wainwright, {Derek A.}",

note = "Funding Information: This work was supported by NIH grants R00 NS082381 (D.A.W.); R01 NS097851-01 (D.A.W.); National Cancer Institute P50 CA221747 Project 2 (D.A.W. and R.V.L.), and T32 CA0070085 (E.L.). Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2019",

month = mar,

day = "4",

doi = "10.1080/2162402X.2018.1548242",

language = "English (US)",

volume = "8",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "3",

}

Zhai, L, Ladomersky, E, Lauing, KL, Wu, M, Scholtens, DM, Savoor, R, Zhang, B , Wu, JD , Horbinski, C , Lukas, RV, Binder, DC & Wainwright, DA 2019, 'Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)', OncoImmunology, vol. 8, no. 3, 1548242. https://doi.org/10.1080/2162402X.2018.1548242

TY - JOUR

T1 - Commentary

T2 - preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

AU - Zhai, Lijie

AU - Ladomersky, Erik

AU - Lauing, Kristen L.

AU - Wu, Meijing

AU - Scholtens, Denise M.

AU - Savoor, Rohan

AU - Zhang, Bin

AU - Wu, Jennifer D.

AU - Horbinski, Craig

AU - Lukas, Rimas V.

AU - Binder, David C.

AU - Wainwright, Derek A.

N1 - Funding Information: This work was supported by NIH grants R00 NS082381 (D.A.W.); R01 NS097851-01 (D.A.W.); National Cancer Institute P50 CA221747 Project 2 (D.A.W. and R.V.L.), and T32 CA0070085 (E.L.). Publisher Copyright: © 2018, © 2018 Taylor & Francis Group, LLC.

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

AB - Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

KW - IDO

KW - Treg

KW - brain tumor

KW - glioblastoma

KW - immunosuppression

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85058708960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058708960&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1548242

DO - 10.1080/2162402X.2018.1548242

M3 - Comment/debate

C2 - 30723577

AN - SCOPUS:85058708960

SN - 2162-4011

VL - 8

JO - OncoImmunology

JF - OncoImmunology

IS - 3

M1 - 1548242

ER -

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this